HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

This was the stock's third consecutive day of gains.

TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...

Analysts have provided new insights into AbbVie and Esperion, two major players in the healthcare sector. AbbVie’s stock has ...

On June 17, 2025, the Tax Court opinion in AbbVie Inc. and Subsidiaries v. Commissioner of Internal Revenue was ...

Investors are digesting Trump's stiff tariffs on imports from more than a dozen countries and delayed the return of sweeping ...

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Neurocrine Biosciences' potential shines with robust assets, strong pipeline, and growth opportunities. Learn more about NBIX ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Advance‑decline metrics reveal ~52% of stocks up: modest daily gains, but with a positive trend in new highs (~7%) versus low occurrences (~1%). Broader market participation beyond mega‑cap tech is ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...